Temsirolimus

Drug Profile

Temsirolimus

Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; Torisel

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Johann Wolfgang Goethe Universitatsklinikum; Multiple Myeloma Research Consortium; NCIC Clinical Trials Group; Pfizer; Wyeth
  • Class Antineoplastics; Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Renal cell carcinoma
  • Phase II Acute myeloid leukaemia; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Phase I/II Follicular lymphoma; Head and neck cancer
  • Phase I Acute lymphoblastic leukaemia; Colorectal cancer; Lymphoma; Solid tumours
  • No development reported Multiple myeloma; Prostate cancer
  • Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 19 Sep 2017 Johannes Gutenberg University Mainz and Pfizer completes a phase I/II trial in Follicular lymphoma or Mantle cell lymphoma in Germany (NCT01078142)
  • 26 Apr 2017 Pfizer completes a phase II trial in Acute myeloid leukaemia (Newly diagnosed, In adults, In the elderly, Second-line therapy or greater) in Germany (IV) (NCT01611116)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top